Home
Kiniksa Pharmaceuticals International, Plc
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
Published Jun 29 2020
4 min read

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

  • Primary and all major secondary efficacy endpoints were highly statistically significant 
  • Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p